The Cancer Letter

Inside information on cancer research and drug development

In the Archives

Advocacy and advances: The DOD Breast Cancer Research Program, immunotherapy, and annual reports

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Spotlight article

Advocacy in Action: The DOD Breast Cancer Research Program
By National Breast Cancer Coalition | September 2, 2021

At first glance, the Department of Defense and breast cancer research might not seem like an easy or natural fit.

And that’s just how the National Breast Cancer Coalition (NBCC) would have it. NBCC is an organization that pushes against the status quo, so finding innovative solutions to complicated problems is a hallmark of their work. The Department of Defense Breast Cancer Research Program (DOD BCRP) is an example of how NBCC advocates pushed boundaries to pursue critical research funding and changes to the system of research that incorporate advocates and support meaningful results.

Recent contributions

Thomas Dougherty, PhD: Pioneer of Photodynamic Therapy
By Roswell Park Comprehensive Cancer Center | September 2, 2021

Documentary profiles Dr. James P. Allison and his Nobel Prize-winning immunotherapy research
By ASCO | September 2, 2021

Fran Visco: President of the National Breast Cancer Coalition
By National Breast Cancer Coalition | September 1, 2021

ASCO Clinical Cancer Advances

Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2009: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2008: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2007: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2006: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2005: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

This column features the latest posts to the Cancer History Project by our growing list of contributors. 

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account